1 型糖尿病（T1D）は、膵臓がインスリン（人々が食物からエネルギーを得ることを可能にするホルモン）の産生を停止する自己免疫疾患です。これは、体の免疫系がベータ細胞と呼ばれる膵臓のインスリン産生細胞を攻撃して破壊するときに発生します。1型糖尿病の危険因子には、遺伝学と家族歴、膵臓の病気、感染症または病気が含まれます。1 型糖尿病の徴候と症状には、喉の渇きと頻尿、極度の空腹、体重減少、疲労、過敏症、または異常な行動が含まれます。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Type 1 Diabetes (Juvenile Diabetes) - Overview
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
Type 1 Diabetes (Juvenile Diabetes) - Drug Profiles
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products
Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, 2022
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
